METOCLOPRAMIDE Drug Patent Profile

When do Metoclopramide patents expire, and when can generic versions of Metoclopramide launch?

Metoclopramide is a drug marketed by Avet Lifesciences, Bedford, Fresenius Kabi Usa, Hospira, Lyphomed, Norbrook, Smith And Nephew, Teva Pharms Usa, Actavis Mid Atlantic, Ani Pharms, Chartwell Molecular, Genus, Morton Grove, Paco, Pharmobedient Cnsltg, Roxane, Teva, Vistapharm Llc, Novel Labs Inc, Aiping Pharm Inc, Chartwell Rx, Clonmel, Halsey, Impax Labs Inc, Interpharm, Ipca Labs Ltd, Mutual Pharm, Northstar Hlthcare, Par Pharm, Sandoz, Schering, Strides Pharma Intl, Sun Pharm Industries, Superpharm, Usl Pharma, and Watson Labs. and is included in fifty-five NDAs.

The generic ingredient in METOCLOPRAMIDE is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Metoclopramide

A generic version of METOCLOPRAMIDE was approved as metoclopramide hydrochloride by TEVA on July 29^th, 1985.

Summary for METOCLOPRAMIDE

US Patents:	0
Applicants:	36
NDAs:	55
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	306
Patent Applications:	4,687
Drug Prices:	Drug price information for METOCLOPRAMIDE
What excipients (inactive ingredients) are in METOCLOPRAMIDE?	METOCLOPRAMIDE excipients list
DailyMed Link:	METOCLOPRAMIDE at DailyMed

See drug prices for METOCLOPRAMIDE

See drug sales revenues for METOCLOPRAMIDE

Recent Clinical Trials for METOCLOPRAMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
Mercy Bon Secours Saint Vincent Medical Center	PHASE3
Umraniye Education and Research Hospital	NA

See all METOCLOPRAMIDE clinical trials

Pharmacology for METOCLOPRAMIDE

Drug Class	Dopamine-2 Receptor Antagonist
Mechanism of Action	Dopamine D2 Antagonists

US Patents and Regulatory Information for METOCLOPRAMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ipca Labs Ltd	METOCLOPRAMIDE HYDROCHLORIDE	metoclopramide hydrochloride	TABLET;ORAL	078807-001	Jun 12, 2008	AB	RX	No	No
Aiping Pharm Inc	METOCLOPRAMIDE HYDROCHLORIDE	metoclopramide hydrochloride	TABLET;ORAL	072215-002	Nov 5, 2024	AB	RX	No	No
Schering	METOCLOPRAMIDE HYDROCHLORIDE	metoclopramide hydrochloride	TABLET;ORAL	070598-001	Feb 2, 1987		DISCN	No	No
Watson Labs	METOCLOPRAMIDE HYDROCHLORIDE	metoclopramide hydrochloride	TABLET;ORAL	070453-001	Jun 6, 1986		DISCN	No	No

Market Dynamics and Financial Trajectory for Metoclopramide

Last updated: March 3, 2026

What is the Current Market Size and Growth Outlook for Metoclopramide?

Metoclopramide is a dopamine antagonist primarily used for gastrointestinal conditions such as nausea, vomiting, and gastroparesis. As of 2022, the global market for metoclopramide was valued at approximately USD 400 million, with a compound annual growth rate (CAGR) projected at 2.5% over the next five years.

Regional Market Breakdown (2022)

Region	Market Value (USD)	Share of Total Market	Key Drivers
North America	150 million	37.5%	High prevalence of GI disorders, extensive healthcare infrastructure
Europe	100 million	25%	Aging population, regulatory approvals
Asia Pacific	70 million	17.5%	Growing awareness, expanding healthcare systems
Latin America	40 million	10%	Increasing pharmaceutical penetration
Middle East & Africa	40 million	10%	Rising demand for GI medications

The North American market dominates due to well-established prescribing practices and high awareness; Asia Pacific presents the fastest growth due to increasing healthcare access.

How Do Patent Statuses and Regulatory Policies Impact the Market?

Metoclopramide has been available as a generic drug since patent expiration in the late 1990s. The drug’s primary patent was filed by Roche in 1960 and expired around 1999, enabling multiple generic manufacturers to penetrate the market.

Regulatory Considerations

• The U.S. Food and Drug Administration (FDA) approved metoclopramide in 1979.
• The European Medicines Agency (EMA) approved the drug in the 1980s.
• Safety warnings issued by regulatory agencies restrict high-dose or long-term use due to risks of tardive dyskinesia and other neurological adverse effects (FDA, 2009).

These safety concerns have led to restrictions or label updates, influencing prescribing behaviors and market volume.

Who Are the Key Market Players and What Is Their Financial Position?

The market is highly fragmented with generic manufacturers leading. Major players include:

Company	Product Portfolio	Revenue Contribution (Approximate)
Teva Pharmaceuticals	Multiple generics including metoclopramide	45% of global sales
Sandoz (Novartis)	Generic formulations	20%
Mylan	Broad generic portfolio	15%
Others	Regional and smaller generic firms	20%

No proprietary branded formulation holds significant market share; the majority of revenue derives from generics.

What Are the Key Market Trends and Drivers?

1. Rising Incidence of Gastrointestinal Disorders
   Increasing cases of gastroparesis, GERD, and chemotherapy-induced nausea enhance demand.

2. Preference for Orally Administered Drugs
   Availability of oral formulations supports outpatient treatment, expanding market access.

3. Regulatory Restrictions
   Safety warnings restrict long-term or high-dose use, constraining volume growth.

4. Emergence of Alternatives and New Delivery Systems
   Innovations such as transdermal patches and injectables may influence future market dynamics.

What Are the Financial Risks and Opportunities?

Risks

• Safety concerns limit off-label use and long-term prescriptions.
• Regulatory restrictions reduce potential growth, especially in markets with strict guidelines.
• Competition from newer antiemetics like 5-HT3 antagonists (e.g., ondansetron) affects market share.

Opportunities

• Special formulations targeting specific patient populations.
• Market expansion in emerging regions with improving healthcare infrastructure.
• Potential brand development for new delivery methods with better safety profiles.

How Will Market Revenue Evolve Over the Next Five Years?

Projected revenue growth for metoclopramide is modest, driven by increased GI disorder prevalence and expanding healthcare access in emerging markets.

Year	Projected Market Size (USD Millions)	CAGR	Key Assumptions
2023	410	2.5%	Stable regulatory environment
2024	420	2.4%	Continued demand, slow innovation
2025	430	2.3%	No significant regulatory changes
2026	440	2.2%	Market saturation in mature regions
2027	450	2.0%	Emerging markets offset mature market decline

What Are the Main Considerations for Stakeholders?

• Developers should consider formulation innovations to address safety concerns.
• Investors need to evaluate the generic market saturation and regulatory environment.
• Manufacturers may explore regional expansions to capitalize on emerging healthcare access.

Key Takeaways

• The global metoclopramide market is valued around USD 400 million with steady but slow growth.
• Generics dominate the market following patent expiration, with no significant branded leaders.
• Safety issues and regulatory restrictions limit growth potential but do not prevent market expansion in emerging economies.
• The primary drivers include rising incidence of GI disorders and healthcare infrastructure expansion.
• Opportunities exist in developing safer formulations and targeting emerging markets for growth.

FAQs

1. What is the primary use of metoclopramide?
It treats nausea, vomiting, and gastroparesis by enhancing gastric motility and reducing reflux.

2. How does safety concern impact the market?
Risks of neurological side effects restrict long-term use and lead to regulatory restrictions, limiting growth.

3. Are there branded versions of metoclopramide?
No; the market predominantly consists of generics following patent expiry.

4. What are upcoming innovations for this drug?
Research focuses on new delivery systems such as patches and improved formulations with reduced side effects.

5. How do regional differences affect market prospects?
Developed markets restrict use, while emerging markets experience growth due to expanding healthcare services and rising disease prevalence.

---

References

[1] Food and Drug Administration. (2009). Safety warning for metoclopramide. FDA.gov.
[2] MarketWatch. (2022). Global gastrointestinal drugs market report.
[3] IMS Health. (2022). Pharmaceutical market data and analysis.
[4] European Medicines Agency. (2009). Summary of product characteristics for metoclopramide.
[5] Statista. (2022). Market size of gastrointestinal drugs worldwide.